Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Bought by Swiss National Bank

Swiss National Bank boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 24.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 150,600 shares of the company's stock after acquiring an additional 29,600 shares during the quarter. Swiss National Bank owned about 0.07% of Cellebrite DI worth $3,318,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HighTower Advisors LLC purchased a new stake in Cellebrite DI in the fourth quarter valued at approximately $274,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at $8,126,000. Raymond James Financial Inc. purchased a new stake in shares of Cellebrite DI in the 4th quarter valued at $9,995,000. Aigen Investment Management LP lifted its stake in Cellebrite DI by 16.9% during the 4th quarter. Aigen Investment Management LP now owns 52,595 shares of the company's stock worth $1,159,000 after acquiring an additional 7,598 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in Cellebrite DI in the 4th quarter valued at about $234,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on CLBT shares. Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Thursday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $23.43.

Remove Ads

Cellebrite DI Price Performance

Shares of CLBT traded down $0.15 during mid-day trading on Friday, reaching $19.46. The company's stock had a trading volume of 902,130 shares, compared to its average volume of 1,396,209. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The stock has a market cap of $4.66 billion, a PE ratio of -14.00, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The company's 50 day moving average is $20.85 and its 200 day moving average is $19.91.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.